Valion Bio, Inc.
VBIOHealthcare|Biotechnology|US
$0.51
+0.01 (+1.57%)
DCF Value
$5.14
Tangible Book / Share
$45.75
Cash / Share
$15.59
Financials
Financial Snapshot
Market Cap
$1.1M
Enterprise Value
$16.4M
Revenue (TTM)
-$156.0K
Net Income (TTM)
-$18.8M
Cash & Investments
$2.1M
Net Cash
-$15.3M
Free Cash Flow (TTM)
-$14.7M
Operating CF (TTM)
-$14.6M
Debt/Equity
1.46
Cash Runway & Burn Rate
Cash on Hand
$2.1M
Quarterly Burn
$3.6M
Monthly Burn
$1.2M
Est. Runway
~0.6 quarters
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $2.3M | $1.0M | $13.0M | $3.5M | $3.4M | $2.0M | $12.6M | $2.1M | |
| Operating Cash Flow | -$3.7M | -$3.0M | -$5.6M | -$8.9M | -$8.5M | -$5.7M | -$7.0M | -$14.6M | |
| Free Cash Flow | -$3.7M | -$3.0M | -$5.6M | -$8.9M | -$8.6M | -$5.7M | -$7.0M | -$14.7M | |
| Capital Expenditure | -$31.0K | $0.00 | $0.00 | -$11.0K | -$118.0K | $0.00 | -$38.0K | -$99.0K | |
| Financing Cash Flow | $5.6M | $1.8M | $17.5M | -$528.0K | $8.5M | $4.3M | $18.3M | $16.1M |
R&D Spending
R&D (TTM)
$6.7M
R&D Intensity
—
R&D Growth vs Prior
+114.0%
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $420.0K | $860.0K | $1.3M | $1.8M | $1.2M | $0.00 | $0.00 | -$156.0K | |
| R&D Expense | $986.0K | $768.0K | $870.0K | $1.7M | $1.7M | $1.3M | $3.1M | $6.7M | |
| R&D % of Revenue | 234.8% | 89.3% | 69.2% | 94.0% | 140.7% | — | — | -4294.2% | |
| SG&A | $2.4M | $2.3M | $4.7M | $8.7M | $6.9M | $2.8M | $4.8M | $9.7M |
Income Statement
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $420.0K | $860.0K | $1.3M | $1.8M | $1.2M | $0.00 | $0.00 | -$156.0K | |
| Cost of Revenue | $713.0K | $1.1M | $1.3M | $1.5M | $889.0K | $352.0K | $0.00 | $649.0K | |
| Gross Profit | -$293.0K | -$233.0K | -$46.0K | $299.0K | $287.0K | -$352.0K | $0.00 | -$805.0K | |
| R&D | $986.0K | $768.0K | $870.0K | $1.7M | $1.7M | $1.3M | $3.1M | $6.7M | |
| SG&A | $2.4M | $2.3M | $4.7M | $8.7M | $6.9M | $2.8M | $4.8M | $9.7M | |
| Operating Income | -$3.6M | -$3.3M | -$5.6M | -$10.1M | -$8.2M | -$4.4M | -$7.9M | -$16.5M | |
| Interest Expense | $443.0K | $423.0K | $1.8M | $0.00 | $0.00 | $0.00 | $146.0K | $1.3M | |
| Pretax Income | -$4.1M | -$3.6M | -$8.5M | -$10.1M | -$8.2M | -$4.5M | -$8.0M | -$17.8M | |
| Net Income | -$4.1M | -$3.6M | -$8.5M | -$10.1M | -$8.2M | -$5.7M | -$8.9M | -$18.8M | |
| EPS (Diluted) | -761.09 | -667.69 | -4133.60 | -1768.00 | -176.80 | -19.68 | -7.84 | -111.97 | |
| EBITDA | -$3.6M | -$3.3M | -$5.6M | -$9.9M | -$8.1M | -$4.1M | -$7.8M | -$15.6M | |
| Shares Out. (M) | 0.01 | 0.01 | 0.00 | 0.01 | 0.05 | 0.29 | 1.16 | 0.14 |
Balance Sheet
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $2.3M | $1.0M | $13.0M | $3.5M | $3.4M | $2.0M | $12.6M | $2.1M | |
| Short-Term Investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Current Assets | $3.0M | $1.5M | $14.3M | $5.3M | $4.7M | $2.6M | $13.0M | $3.4M | |
| Total Assets | $3.0M | $1.5M | $15.0M | $5.9M | $5.2M | $2.8M | $31.6M | $32.5M | |
| Total Current Liabilities | $653.0K | $1.3M | $1.2M | $1.9M | $1.4M | $272.0K | $646.0K | $3.0M | |
| Long-Term Debt | $0.00 | $1.4M | $0.00 | $0.00 | $0.00 | $0.00 | $6.5M | $7.4M | |
| Total Liabilities | $653.0K | $2.7M | $1.8M | $2.2M | $1.6M | $272.0K | $14.8M | $20.6M | |
| Stockholders' Equity | $2.4M | -$1.2M | $13.3M | $3.6M | $3.6M | $2.5M | $16.8M | $11.9M | |
| Retained Earnings | -$7.4M | -$11.1M | -$19.5M | -$29.6M | -$37.9M | -$43.5M | -$52.6M | -$66.5M |
Cash Flow Statement
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$3.7M | -$3.0M | -$5.6M | -$8.9M | -$8.5M | -$5.7M | -$7.0M | -$14.6M | |
| Capital Expenditure | -$31.0K | $0.00 | $0.00 | -$11.0K | -$118.0K | $0.00 | -$38.0K | -$99.0K | |
| Free Cash Flow | -$3.7M | -$3.0M | -$5.6M | -$8.9M | -$8.6M | -$5.7M | -$7.0M | -$14.7M | |
| Investing Cash Flow | -$31.0K | $0.00 | $0.00 | -$11.0K | -$118.0K | $0.00 | -$705.0K | -$223.0K | |
| Financing Cash Flow | $5.6M | $1.8M | $17.5M | -$528.0K | $8.5M | $4.3M | $18.3M | $16.1M | |
| Issuance of Stock | $3.8M | $13.0K | $14.9M | $0.00 | $8.5M | $4.4M | $18.5M | $4.5M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | $1.7M | $1.7M | $2.6M | $0.00 | $0.00 | $0.00 | -$172.0K | $0.00 | |
| Stock Based Comp. | $0.00 | $0.00 | $0.00 | $398.0K | $271.0K | $229.0K | $564.0K | $496.0K | |
| Net Change in Cash | $2.3M | -$1.3M | $11.9M | -$9.5M | -$122.0K | -$1.4M | $10.6M | $1.3M |
Dilution Tracker
Shares outstanding grew 21102.4% over 5 years — significant dilution
Shares Outstanding
2M
5-Year Share Growth
+21102.4%
Stock Issuance (TTM)
$4.5M
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 0.01 | 0.01 | 0.00 | 0.01 | 0.05 | 0.29 | 1.16 | 0.14 | |
| Change vs Prior % | — | 0.0% | -62.3% | 177.0% | 720.0% | 516.0% | 302.1% | -88.3% | |
| Stock Issuance | $3.8M | $13.0K | $14.9M | $0.00 | $8.5M | $4.4M | $18.5M | $4.5M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $0.00 | $0.00 | $0.00 | $398.0K | $271.0K | $229.0K | $564.0K | $496.0K |
Margins & Profitability
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | -69.8% | -27.1% | -3.7% | 16.3% | 24.4% | — | — | 516.0% | |
| Operating Margin % | -867.4% | -386.2% | -448.1% | -548.8% | -701.1% | — | — | 10587.2% | |
| Net Margin % | -987.6% | -423.1% | -675.7% | -548.7% | -701.0% | — | — | 12019.2% | |
| EBITDA Margin % | -866.4% | -385.2% | -446.2% | -539.3% | -685.6% | — | — | 9972.4% | |
| FCF Margin % | -881.2% | -352.0% | -446.5% | -485.3% | -733.8% | — | — | 9406.4% | |
| ROE % | -174.9% | 309.2% | -64.0% | -278.1% | -230.3% | -223.1% | -52.9% | -165.4% | |
| ROA % | -137.2% | -237.7% | -56.5% | -171.8% | -159.9% | -201.5% | -28.1% | -57.7% | |
| ROIC % | -153.6% | -1137.3% | -40.3% | -242.7% | -208.8% | -174.2% | -25.5% | -55.1% | |
| R&D / Revenue % | 234.8% | 89.3% | 69.2% | 94.0% | 140.7% | — | — | -4294.2% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.0% | 104.8% | 46.2% | 46.4% | -36.1% | -100.0% | 0.0% | |
| Gross Profit | 0.0% | 20.5% | 80.3% | 750.0% | -4.0% | -222.6% | 100.0% | |
| Operating Income | 0.0% | 8.8% | -69.6% | -79.3% | 18.4% | 46.4% | -78.8% | |
| Net Income | 0.0% | 12.3% | -133.4% | -18.9% | 18.3% | 31.4% | -57.0% | |
| EPS (Diluted) | 0.0% | 12.3% | -519.1% | 57.2% | 90.0% | 88.9% | 60.2% | |
| Operating Cash Flow | 0.0% | 17.5% | -85.4% | -58.9% | 4.6% | 32.7% | -22.3% | |
| Free Cash Flow | 0.0% | 18.2% | -85.4% | -59.1% | 3.4% | 33.7% | -22.9% | |
| R&D Expense | 0.0% | -22.1% | 13.3% | 98.9% | -4.3% | -20.7% | 138.5% | |
| SG&A Expense | 0.0% | -1.9% | 103.3% | 83.7% | -20.7% | -60.0% | 73.1% | |
| Total Assets | 0.0% | -49.4% | 882.1% | -60.9% | -12.2% | -45.6% | 1026.0% | |
| Book Value / Share | 0.0% | -149.6% | 3092.0% | -90.1% | -88.0% | -88.5% | 64.8% | |
| Debt | 0.0% | 0.0% | -51.8% | -25.1% | -30.4% | -100.0% | 0.0% | |
| Diluted Shares | 0.0% | 0.0% | -62.3% | 177.0% | 720.0% | 516.0% | 302.1% |
Valuation
P/E (TTM)At Loss
P/S-7.05
10Y Low / Med / High30.35 / 269.45 / 2862.22
P/B0.01
10Y Low / Med / High2.49 / 25.52 / 507.02
EV/EBITDAAt Loss
EV/Revenue-105.13
10Y Low / Med / High27.77 / 259.70 / 2856.72
P/FCFAt Loss
Intrinsic Value Models (per share)
DCF Value
$5.14
Tangible Book / Share
$45.75
Cash / Share
$15.59
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -289.81 | -330.36 | -39.89 | -15.38 | -4.33 | -7.48 | -4.62 | -0.00 | |
| P/S Ratio | 2862.22 | 1397.83 | 269.45 | 84.09 | 30.35 | 0.00 | 0.00 | -7.05 | |
| P/B Ratio | 507.02 | -1021.35 | 25.52 | 42.62 | 9.97 | 16.68 | 2.49 | 0.01 | |
| EV/EBITDA | -329.71 | -362.98 | -58.20 | -15.29 | -4.05 | -9.91 | -4.55 | -1.05 | |
| EV/Revenue | 2856.72 | 1398.32 | 259.70 | 82.46 | 27.77 | 0.00 | 0.00 | -105.13 |
Analyst Estimates & Quality
Altman Z-Score
-4.49
Distress
Piotroski F-Score
2
Weak
Revenue Segments
By Product
| Segment | 2024 |
|---|---|
| Shipping and Handling | $3.0K |